AR013758A1 - COMBINATION THERAPY FOR THE TREATMENT OF AIDS. - Google Patents
COMBINATION THERAPY FOR THE TREATMENT OF AIDS.Info
- Publication number
- AR013758A1 AR013758A1 ARP980105720A ARP980105720A AR013758A1 AR 013758 A1 AR013758 A1 AR 013758A1 AR P980105720 A ARP980105720 A AR P980105720A AR P980105720 A ARP980105720 A AR P980105720A AR 013758 A1 AR013758 A1 AR 013758A1
- Authority
- AR
- Argentina
- Prior art keywords
- aids
- reverse transcriptase
- treatment
- protease
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La combinacion del compuesto A inhibir de proteasa HIV y uno o más inhibidores de transcriptasa inversa nucluosídicos, inhibidores detranscriptasa inversa no nucleosídicos, o inhibidores de proteasa tales como II es util en la inhibicion dela proteasa HIV, la inhibicion de la transcriptasainversa HIV, la prevencion o tratamiento de SIDA ya sea como compuestos, o como sales o ésteres farmacéuticametne aceptables, ingredientes para composicionesfarmacéuticas, y en combinacion o no con otros antivirales inmunomoduladores antibioticos o vacunas. También se describen métodos para tratar SIDA y métodospara evitar o tratar las infeciones causadas por HIV.The combination of compound A to inhibit HIV protease and one or more nucluoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, or protease inhibitors such as II is useful in inhibiting HIV protease, inhibiting HIV reverse transcriptase, preventing or treatment of AIDS either as compounds, or as pharmaceutically acceptable salts or esters, ingredients for pharmaceutical compositions, and in combination or not with other antibiotic immunomodulatory antivirals or vaccines. Methods to treat AIDS and methods to prevent or treat HIV infections are also described.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6542197P | 1997-11-13 | 1997-11-13 | |
| GBGB9807938.7A GB9807938D0 (en) | 1998-04-15 | 1998-04-15 | Combination therapy for the treatment of AIDS |
| US9094098P | 1998-06-26 | 1998-06-26 | |
| GBGB9819590.2A GB9819590D0 (en) | 1998-09-08 | 1998-09-08 | Combination therapy for the treatment of aids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013758A1 true AR013758A1 (en) | 2001-01-10 |
Family
ID=27451773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105720A AR013758A1 (en) | 1997-11-13 | 1998-11-12 | COMBINATION THERAPY FOR THE TREATMENT OF AIDS. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1044000B1 (en) |
| JP (1) | JP2001522889A (en) |
| KR (1) | KR20010032055A (en) |
| CN (1) | CN1285747A (en) |
| AR (1) | AR013758A1 (en) |
| AT (1) | ATE218866T1 (en) |
| AU (1) | AU749795B2 (en) |
| BG (1) | BG104507A (en) |
| BR (1) | BR9814146A (en) |
| CA (1) | CA2309164A1 (en) |
| CO (1) | CO4970782A1 (en) |
| DE (1) | DE69806062T2 (en) |
| EA (1) | EA200000513A1 (en) |
| ES (1) | ES2177103T3 (en) |
| HU (1) | HUP0100365A3 (en) |
| ID (1) | ID24922A (en) |
| IL (1) | IL135994A0 (en) |
| IS (1) | IS5481A (en) |
| NO (1) | NO20002481L (en) |
| PE (1) | PE20000020A1 (en) |
| PL (1) | PL340430A1 (en) |
| SK (1) | SK6842000A3 (en) |
| TR (1) | TR200001938T2 (en) |
| WO (1) | WO1999025352A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| US7462733B2 (en) | 2001-07-30 | 2008-12-09 | University Of Southern California | Preparation and use of α-keto phosphonates |
| ATE398455T1 (en) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR ANTIVIRAL COMBINATION THERAPY |
| GB2400553A (en) * | 2003-04-14 | 2004-10-20 | Cipla Ltd | Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (en) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69430385T2 (en) * | 1993-12-15 | 2002-11-07 | Merck & Co., Inc. | HIV Protease Inhibitors |
-
1998
- 1998-11-11 CO CO98066470A patent/CO4970782A1/en unknown
- 1998-11-12 AU AU15225/99A patent/AU749795B2/en not_active Ceased
- 1998-11-12 DE DE69806062T patent/DE69806062T2/en not_active Expired - Fee Related
- 1998-11-12 ID IDW20000895A patent/ID24922A/en unknown
- 1998-11-12 IL IL13599498A patent/IL135994A0/en unknown
- 1998-11-12 SK SK684-2000A patent/SK6842000A3/en unknown
- 1998-11-12 EP EP98959424A patent/EP1044000B1/en not_active Expired - Lifetime
- 1998-11-12 KR KR1020007005176A patent/KR20010032055A/en not_active Application Discontinuation
- 1998-11-12 JP JP2000520785A patent/JP2001522889A/en not_active Withdrawn
- 1998-11-12 TR TR2000/01938T patent/TR200001938T2/en unknown
- 1998-11-12 PL PL98340430A patent/PL340430A1/en unknown
- 1998-11-12 EA EA200000513A patent/EA200000513A1/en unknown
- 1998-11-12 CA CA002309164A patent/CA2309164A1/en not_active Abandoned
- 1998-11-12 ES ES98959424T patent/ES2177103T3/en not_active Expired - Lifetime
- 1998-11-12 HU HU0100365A patent/HUP0100365A3/en unknown
- 1998-11-12 AR ARP980105720A patent/AR013758A1/en unknown
- 1998-11-12 CN CN98813077A patent/CN1285747A/en active Pending
- 1998-11-12 AT AT98959424T patent/ATE218866T1/en not_active IP Right Cessation
- 1998-11-12 BR BR9814146-5A patent/BR9814146A/en not_active Application Discontinuation
- 1998-11-12 WO PCT/US1998/024097 patent/WO1999025352A1/en not_active Application Discontinuation
- 1998-11-12 PE PE1998001094A patent/PE20000020A1/en not_active Application Discontinuation
-
2000
- 2000-05-09 IS IS5481A patent/IS5481A/en unknown
- 2000-05-12 NO NO20002481A patent/NO20002481L/en not_active Application Discontinuation
- 2000-06-05 BG BG104507A patent/BG104507A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200001938T2 (en) | 2001-07-23 |
| CN1285747A (en) | 2001-02-28 |
| IL135994A0 (en) | 2001-05-20 |
| SK6842000A3 (en) | 2000-12-11 |
| NO20002481L (en) | 2000-07-12 |
| KR20010032055A (en) | 2001-04-16 |
| IS5481A (en) | 2000-05-09 |
| BR9814146A (en) | 2000-10-03 |
| PL340430A1 (en) | 2001-02-12 |
| AU1522599A (en) | 1999-06-07 |
| AU749795B2 (en) | 2002-07-04 |
| HUP0100365A2 (en) | 2002-05-29 |
| ID24922A (en) | 2000-08-31 |
| EP1044000A1 (en) | 2000-10-18 |
| PE20000020A1 (en) | 2000-01-27 |
| CO4970782A1 (en) | 2000-11-07 |
| EP1044000B1 (en) | 2002-06-12 |
| NO20002481D0 (en) | 2000-05-12 |
| HUP0100365A3 (en) | 2002-06-28 |
| JP2001522889A (en) | 2001-11-20 |
| DE69806062T2 (en) | 2003-03-20 |
| ATE218866T1 (en) | 2002-06-15 |
| WO1999025352A1 (en) | 1999-05-27 |
| EA200000513A1 (en) | 2000-10-30 |
| CA2309164A1 (en) | 1999-05-27 |
| ES2177103T3 (en) | 2002-12-01 |
| DE69806062D1 (en) | 2002-07-18 |
| BG104507A (en) | 2001-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9204720A (en) | QUINAZOLINE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS. | |
| ES2125251T3 (en) | HIV PROTEASE INHIBITORS. | |
| ES2188604T3 (en) | HIV PROTEASE INHIBITORS IN PHARMACEUTICAL COMBINATIONS FOR AIDS TREATMENT. | |
| ATE377011T1 (en) | GAMMA-HYDROXY-2-(FLUORALKYLAMINOCARBONYL)-1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR | |
| MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
| YU172991A (en) | SYNERGISM OF HIV REVERSE TRANSCRIPTASE INHIBITORS | |
| ES2174921T3 (en) | HIV PROTEASE INHIBITORS. | |
| AR013758A1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF AIDS. | |
| MX9302681A (en) | NEW QUINAZOLINS AS REVERSE HIV TRANSCRIPTASE INHIBITORS. | |
| EA199700150A1 (en) | COMBINED TREATMENT WITH RESPECT OF HIV INFECTION USING HIV PROTASE INHIBITOR INDINAVIAR AND REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, ddI OR ddC | |
| MX9700036A (en) | Combination therapy for hiv infection. | |
| ECSP982741A (en) | COMBINED THERAPY FOR THE TREATMENT OF AIDS | |
| ES2190456T3 (en) | COMBINATION OF HIV PROTEASE INHIBITORS. | |
| ECSP961660A (en) | COMBINED THERAPY FOR HIV INFECTION | |
| ECSP003786A (en) | RANGE-HYDROXIL-2 (FLUOROALQUILOAMINOCARBONIL) -1-PIPERACINAPENTANAMIDAS AND USES OF THEM | |
| ECSP900707A (en) | AMINO ACID DERIVATIVES |